# Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors

> **NCT05153096** · PHASE1 · UNKNOWN · sponsor: **NovaRock Biotherapeutics, Ltd** · enrollment: 410 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** NBL-015

## Key facts

- **NCT ID:** NCT05153096
- **Lead sponsor:** NovaRock Biotherapeutics, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05153096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05153096, "Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05153096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*